While Bangladesh’s pharmaceutical sector has exceeded expectations and surpassed many comparator countries, the industry’s reliance on imports for raw materials has long been a limiting factor.
Bangladesh’s pharmaceuticals sector is rebounding on the back of smooth imports of raw materials, a well-maintained supply chain, and a higher opening of letters of credit, highlighting the recovery following challenges over the last two years, industry people say.
Big pharmaceutical companies in Bangladesh are gradually taking hold of the country’s growing market for herbal medicines as people are opting for higher quality natural remedies with recognisable brand value.
Bangladeshi conglomerate ACI has completed exporting its first ever shipment of pharmaceutical products to its subsidiary, ACI Healthcare USA, located in the USA.